Basilea Pharmaceutica AG
BPMUF
$67.75
$6.4110.45%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 54.86M | 50.34M | 69.23M | 70.29M | 40.51M |
| Total Other Revenue | 8.16M | 7.48M | 6.07M | 6.16M | 1.67M |
| Total Revenue | 63.01M | 57.82M | 75.30M | 76.45M | 42.18M |
| Cost of Revenue | 37.90M | 34.78M | 36.50M | 37.06M | 28.60M |
| Gross Profit | 25.12M | 23.05M | 38.80M | 39.39M | 13.59M |
| SG&A Expenses | 10.34M | 9.48M | 9.09M | 9.23M | 8.33M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 48.23M | 44.26M | 45.59M | 46.29M | 36.92M |
| Operating Income | 14.78M | 13.56M | 29.71M | 30.17M | 5.26M |
| Income Before Tax | 11.73M | 10.76M | 30.14M | 30.60M | 4.05M |
| Income Tax Expenses | 2.15M | 1.97M | -2.23M | -2.27M | -7.42M |
| Earnings from Continuing Operations | 9.58M | 8.79M | 32.37M | 32.87M | 11.47M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.58M | 8.79M | 32.37M | 32.87M | 11.47M |
| EBIT | 14.78M | 13.56M | 29.71M | 30.17M | 5.26M |
| EBITDA | 15.21M | 13.96M | 30.62M | 31.09M | 5.61M |
| EPS Basic | 0.78 | 0.72 | 2.68 | 2.72 | 0.95 |
| Normalized Basic EPS | 0.60 | 0.55 | 1.56 | 1.58 | 0.21 |
| EPS Diluted | 0.77 | 0.70 | 2.39 | 2.43 | 0.95 |
| Normalized Diluted EPS | 0.53 | 0.49 | 1.36 | 1.38 | 0.20 |
| Average Basic Shares Outstanding | 12.24M | 12.24M | 12.09M | 12.09M | 12.03M |
| Average Diluted Shares Outstanding | 13.85M | 13.85M | 13.89M | 13.89M | 12.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |